Memorial Hermann Health System   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Houston TX United States (1907)

Organization Overview

First Clinical Trial
2007
NCT00504010
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

James E.Baumgartner, MD | Memorial Hermann | Memorial Hermann Healthcare System | Memorial Hermann Health System | Memorial Hermann Hospital | Memorial Hermann Texas Medical Center

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anterior Cruciate Ligament Injuries (Phase 4)

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Deafness (Phase 1)

Glioblastoma (Phase 2)

Hearing Loss (Phase 1)

Hemophilia A (Phase 3)

Multiple Organ Failure (Phase 2)

Myalgia (Phase 1)

Prostatic Neoplasms (Phase 1)

Spinal Cord Injuries (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stroke (Phase 1)

Systemic Inflammatory Response Syndrome (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial APIs: 19